TiGenix submits MAA to EMA for Cx601 for the treatment of complex perianal fistulas in Crohn’s disease patients

TiGenix obtains commercial production license for Cx601

Minoryx Therapeutics appoints Dr. Khalid Islam as chairman of the board of directors

Aelix Therapeutics completes Series A funding of €11.5M ($12.7M) for therapeutic HIV vaccine

Ysios Capital leads €11.5 M ($12.7 M) Series A funding round in AELIX Therapeutics.

MedLumics Appoints Cardiovascular Device Expert Tim Lenihan to Board of Directors

TiGenix announces acceptance of Cx601 abstract for presentation at ECCO 2016 Congress

TiGenix files Registration Statement for proposed initial public offering in the United States

Leuven (BELGIUM) – December 22, 2015, 22:30h CET – TiGenix NV (Euronext Brussels: TIG; the “Company”), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today that it has filed a Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission for a proposed initial public offering of its American Depository Shares (“ADSs”) to be listed on the NASDAQ Global Market in the United States.

Sanifit announces the creation of a Steering Committee for its Phase 2b ESRD Clinical Program with SNF472

The newly created Steering Committee includes 4 well known scientists and clinicians who will provide the overall supervision of the phase 2b study with SNF472.

Sanifit and Mitelos make available to Doctors and patients a new alternative in osteoporosis

Sanifit and Mitelos have successfully concluded the development, registration and industrial scaled up of SNF671

TiGenix completes enrolment of its Phase I/II study in acute myocardial infarction

Leuven (BELGIUM) – 19th November 2015 – TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today that it has completed enrolment of its Phase II study in acute myocardial Infarction (CAREMI study).